GlassScriptPhysician profile
Nancy J Zidek
NPI 1528048063
$2,233.18
in general payments reported to CMS, 2019-2025
35 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $388 · 2021: $314 · 2022: $253 · 2023: $277 · 2024: $261 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $295.69 | 2019-2025 | Breztri, Airsupra |
| Abbvie INC. | $221.71 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $191.81 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $170.73 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $160.65 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.83 | 2021-2025 | Eohilia, Trintellix |
| Amgen INC. | $98.21 | 2019-2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.46 | 2020-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.82 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $75.07 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $72.25 | 2019-2022 | |
| Amarin Pharma, INC. | $67.98 | 2020-2021 | |
| Mylan Specialty L.P. | $66.67 | 2019-2023 | Yupelri |
| Astellas Pharma US INC | $66.40 | 2020-2021 | |
| Dexcom, INC. | $58.29 | 2023-2025 | Dexcom G6 Transmitter |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $52.15 | 2022 | |
| Ascensia Diabetes Care US INC. | $33.87 | 2025 | |
| Glaxosmithkline, LLC. | $32.80 | 2020-2023 | Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $28.86 | 2024 | Gemtesa |
| Vanda Pharmaceuticals INC. | $24.60 | 2019 | |
| Pfizer INC. | $24.13 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.31 | 2025 | Caplyta |
| Abbott Laboratories | $22.97 | 2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $20.60 | 2023 | Austedo Xr |
| Boston Scientific Corporation | $19.63 | 2024 | Watchman Flx |
| Esperion Therapeutics, INC. | $17.22 | 2021 | |
| Eisai INC. | $16.82 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.59 | 2022 | |
| Merck Sharp & Dohme LLC | $15.18 | 2019 | |
| Neurocrine Biosciences, INC. | $14.03 | 2019 | |
| Viatris Specialty LLC | $13.76 | 2025 | Yupelri |
| Sunovion Pharmaceuticals INC. | $13.72 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.66 | 2021 | |
| Lundbeck LLC | $13.23 | 2024 | Rexulti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Zidek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.